{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:58:25Z","timestamp":1772791105361,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,16]],"date-time":"2014-01-16T00:00:00Z","timestamp":1389830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1745-6215-15-26","type":"journal-article","created":{"date-parts":[[2014,1,16]],"date-time":"2014-01-16T22:02:02Z","timestamp":1389909722000},"source":"Crossref","is-referenced-by-count":56,"title":["The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study"],"prefix":"10.1186","volume":"15","author":[{"given":"Tatsuo","family":"Hosoya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadayoshi","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunya","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Tomino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Makino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwao","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yugo","family":"Shibagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Iimuro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiko","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanari","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,16]]},"reference":[{"key":"1916_CR1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/0002-9343(65)90048-3","volume":"39","author":"WM Mikkelsen","year":"1965","unstructured":"Mikkelsen WM, Dodge HJ, Valkenburg H: The distribution of serum uric acid values in a population unselected as to gout or hyperuricemia: Tecumseh, Michigan 1959\u20131960. Am J Med. 1965, 39: 242-251. 10.1016\/0002-9343(65)90048-3.","journal-title":"Am J Med"},{"key":"1916_CR2","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","volume":"30","author":"H Yamanaka","year":"2011","unstructured":"Yamanaka H, Japanese Society of Gout and Nucleic Acid Metabolism: Japanese for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011, 30: 1018-1029. 10.1080\/15257770.2011.596496.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"1916_CR3","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0272-6386(04)00934-5","volume":"44","author":"K Iseki","year":"2004","unstructured":"Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S: Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004, 44: 642-650.","journal-title":"Am J Kidney Dis"},{"key":"1916_CR4","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1681\/ASN.2007101075","volume":"19","author":"DE Weiner","year":"2008","unstructured":"Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS: Uric acid and incident kidney disease in the community. J Am Soc Nephrol. 2008, 19: 1204-1211. 10.1681\/ASN.2007101075.","journal-title":"J Am Soc Nephrol"},{"key":"1916_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1053\/j.ajkd.2007.05.013","volume":"50","author":"M Chonchol","year":"2007","unstructured":"Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, Kestenbaum B, Carney JK, Fried LF: Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007, 50: 239-247. 10.1053\/j.ajkd.2007.05.013.","journal-title":"Am J Kidney Dis"},{"key":"1916_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMcp1001124","volume":"364","author":"T Neogi","year":"2011","unstructured":"Neogi T: Clinical practice: gout. N Engl J Med. 2011, 364: 443-452. 10.1056\/NEJMcp1001124.","journal-title":"N Engl J Med"},{"key":"1916_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrrheum.2009.236","volume":"6","author":"R Terkeltaub","year":"2010","unstructured":"Terkeltaub R: Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010, 6: 30-38. 10.1038\/nrrheum.2009.236.","journal-title":"Nat Rev Rheumatol"},{"key":"1916_CR8","first-page":"135","volume":"5","author":"S Uchida","year":"2006","unstructured":"Uchida S, Inokami T, Yamashita M: Implication of hyperuricemia and its treatment in progressive renal diseases. Nephrol Fronti. 2006, 5: 135-136.","journal-title":"Nephrol Fronti"},{"key":"1916_CR9","first-page":"1031","volume":"54","author":"Japan Nephrology Society","year":"2012","unstructured":"Japan Nephrology Society: Special issue: Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012 [Article in Japanese]. Nihon Jinzo Gakkai Shi. 2012, 54: 1031-1189.","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"1916_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","volume":"47","author":"YP Siu","year":"2006","unstructured":"Siu YP, Leung KT, Tong MK, Kwan TH: Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006, 47: 51-59. 10.1053\/j.ajkd.2005.10.006.","journal-title":"Am J Kidney Dis"},{"key":"1916_CR11","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2215\/CJN.01580210","volume":"5","author":"M Goicoechea","year":"2010","unstructured":"Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rinc\u00f3n A, Arroyo D, Lu\u00f1o J: Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010, 5: 1388-1393. 10.2215\/CJN.01580210.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1916_CR12","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","volume":"76","author":"Y Takano","year":"2005","unstructured":"Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, Becker MA: Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase. Life Sci. 2005, 76: 1835-1847. 10.1016\/j.lfs.2004.10.031.","journal-title":"Life Sci"},{"key":"1916_CR13","first-page":"269","volume":"32","author":"S Hoshide","year":"2000","unstructured":"Hoshide S, Nishimura S, Ishii S, Matsuzawa K, Saito N, Tanaka T: Metabolites of TMX-67, a new pharmaceutical entity for the treatment of gout or hyperuricemia, and their pharmacokinetic profiles in humans. Drug Metab Rev. 2000, 32: 269-","journal-title":"Drug Metab Rev"},{"key":"1916_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/0091270010365549","volume":"51","author":"BA Grabowski","year":"2011","unstructured":"Grabowski BA, Khosravan R, Vernillet L, Mulford DJ: Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects. J Clin Pharcol. 2011, 51: 189-201. 10.1177\/0091270010365549.","journal-title":"J Clin Pharcol"},{"key":"1916_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/1759720X11416405","volume":"3","author":"I Garcia-Valladares","year":"2011","unstructured":"Garcia-Valladares I, Khan T, Espinoza LR: Efficacy and safety of febuxostat in patients with hyperuricemia and gout. Ther Adv Musculoskelet Dis. 2011, 3: 245-253. 10.1177\/1759720X11416405.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1916_CR16","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/art.20935","volume":"52","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N: Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose\u2013response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005, 52: 916-923. 10.1002\/art.20935.","journal-title":"Arthritis Rheum"},{"key":"1916_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/RHU.0b013e318204aab4","volume":"17","author":"A Whelton","year":"2011","unstructured":"Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L: Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011, 17: 7-13. 10.1097\/RHU.0b013e318204aab4.","journal-title":"J Clin Rheumatol"},{"key":"1916_CR18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","volume":"48","author":"HR Schumacher Jr","year":"2009","unstructured":"Schumacher HR, Becker MA, Lloyd E, MacDonald PA, Lademacher C: Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology. 2009, 48: 188-194.","journal-title":"Rheumatology"},{"key":"1916_CR19","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1097\/RHU.0b013e31822541d0","volume":"17","author":"N Kamatani","year":"2011","unstructured":"Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y: Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout. J Clin Rheumatol. 2011, 17: S50-S56. 10.1097\/RHU.0b013e31822541d0.","journal-title":"J Clin Rheumatol"},{"key":"1916_CR20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/archinte.164.6.659","volume":"164","author":"DS Keith","year":"2004","unstructured":"Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004, 164: 659-663. 10.1001\/archinte.164.6.659.","journal-title":"Arch Intern Med"},{"key":"1916_CR21","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/0002-8703(84)90763-4","volume":"108","author":"WB Kannel","year":"1984","unstructured":"Kannel WB, Stampfer MJ, Castelli WP, Verter J: The prognostic significance of proteinuria: the Framingham study. Am Heart J. 1984, 108: 1347-1352. 10.1016\/0002-8703(84)90763-4.","journal-title":"Am Heart J"},{"key":"1916_CR22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/bmj.300.6720.297","volume":"300","author":"EM Damsgaard","year":"1990","unstructured":"Damsgaard EM, Fr\u00f8land A, J\u00f8rgensen OD, Mogensen CE: Microalbuminuria as predictor of increased mortality in elderly people. BMJ. 1990, 300: 297-300. 10.1136\/bmj.300.6720.297.","journal-title":"BMJ"},{"key":"1916_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1523-1755.2005.00397.x","volume":"68","author":"T Ninomiya","year":"2005","unstructured":"Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, Wakugawa Y, Hata J, Oishi Y, Shikata K, Yonemoto K, Hirakata H, Iida M: Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005, 68: 228-236. 10.1111\/j.1523-1755.2005.00397.x.","journal-title":"Kidney Int"},{"key":"1916_CR24","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1681\/ASN.2006101159","volume":"18","author":"A Kottgen","year":"2007","unstructured":"Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, Chambless LE, Coresh J: Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2007, 18: 1307-1315. 10.1681\/ASN.2006101159.","journal-title":"J Am Soc Nephrol"},{"key":"1916_CR25","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004, 351: 1296-1305. 10.1056\/NEJMoa041031.","journal-title":"N Engl J Med"},{"key":"1916_CR26","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/ki.1997.119","volume":"51","author":"K Iseki","year":"1997","unstructured":"Iseki K, Ikemiya Y, Fukiyama K: Risk factors of end-stage renal disease and serum creatinine in a community-based mass screening. Kidney Int. 1997, 51: 850-854. 10.1038\/ki.1997.119.","journal-title":"Kidney Int"},{"key":"1916_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1291\/hypres.31.433","volume":"31","author":"E Imai","year":"2008","unstructured":"Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Makino H, Hishida A, Matsuo S: Slower decline of glomerular filtration rate in the Japanese general population: A longitudinal 10-year follow-up study. Hypertens Res. 2008, 31: 433-441. 10.1291\/hypres.31.433.","journal-title":"Hypertens Res"},{"key":"1916_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/sj.ki.5000058","volume":"69","author":"BO Eriksen","year":"2006","unstructured":"Eriksen BO, Ingebretsen OC: The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int. 2006, 69: 375-382. 10.1038\/sj.ki.5000058.","journal-title":"Kidney Int"},{"key":"1916_CR29","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11606-010-1511-x","volume":"26","author":"LS Dalrymple","year":"2011","unstructured":"Dalrymple LS, Katz R, Kestenbaum B, Shlipak MG, Sarnak MJ, Stehman-Breen C, Seliger S, Siscovick D, Newman AB, Fried L: Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med. 2011, 26: 379-385. 10.1007\/s11606-010-1511-x.","journal-title":"J Gen Intern Med"},{"key":"1916_CR30","doi-asserted-by":"publisher","first-page":"766","DOI":"10.2215\/CJN.04131206","volume":"2","author":"J Nogueira","year":"2007","unstructured":"Nogueira J, Weir M: The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs. Clin J Am Soc Nephrol. 2007, 2: 766-785. 10.2215\/CJN.04131206.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1916_CR31","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/sj.ki.5000284","volume":"69","author":"F Irie","year":"2006","unstructured":"Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, Kanashiki M, Saito Y, Ota H, Nose T: The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006, 69: 1264-1271. 10.1038\/sj.ki.5000284.","journal-title":"Kidney Int"},{"key":"1916_CR32","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1016\/S0021-9258(18)62820-0","volume":"245","author":"T Spector","year":"1970","unstructured":"Spector T, Johns DG: Stoichiometric inhibition of reduced xanthine oxidase by hydroxypyrazolo [3,4-d]pyrimidines. J Biol Chem. 1970, 245: 5079-5085.","journal-title":"J Biol Chem"},{"key":"1916_CR33","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1016\/S0021-9258(18)63065-0","volume":"245","author":"V Massey","year":"1970","unstructured":"Massey V, Komai H, Palmer G, Elion GB: On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines. J Biol Chem. 1970, 245: 2837-2844.","journal-title":"J Biol Chem"},{"key":"1916_CR34","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1074\/jbc.M208307200","volume":"278","author":"K Okamoto","year":"2003","unstructured":"Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T: An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem. 2003, 278: 1848-1855. 10.1074\/jbc.M208307200.","journal-title":"J Biol Chem"},{"key":"1916_CR35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000028344","volume":"60","author":"T Yamamoto","year":"2000","unstructured":"Yamamoto T, Moriwaki Y, Fujimura Y, Takahashi S, Tsutsumi Z, Tsutsui T, Higashino K, Hada T: Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549. Pharmacology. 2000, 60: 34-40. 10.1159\/000028344.","journal-title":"Pharmacology"},{"key":"1916_CR36","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1161\/hy1101.092839","volume":"38","author":"M Mazzali","year":"2001","unstructured":"Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001, 38: 1101-1106. 10.1161\/hy1101.092839.","journal-title":"Hypertension"},{"key":"1916_CR37","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1097\/01.ASN.0000034910.58454.FD","volume":"13","author":"DH Kang","year":"2002","unstructured":"Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ: A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002, 13: 2888-2897. 10.1097\/01.ASN.0000034910.58454.FD.","journal-title":"J Am Soc Nephrol"},{"key":"1916_CR38","doi-asserted-by":"publisher","first-page":"F991","DOI":"10.1152\/ajprenal.00283.2001","volume":"282","author":"M Mazzali","year":"2002","unstructured":"Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ: Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002, 282: F991-F997.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1916_CR39","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/ndt\/gfm783","volume":"23","author":"LG S\u00e1nchez-Lozada","year":"2008","unstructured":"S\u00e1nchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, Zhao L, Johnson RJ: Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant. 2008, 23: 1179-1185.","journal-title":"Nephrol Dial Transplant"},{"key":"1916_CR40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000127837","volume":"108","author":"LG S\u00e1nchez-Lozada","year":"2008","unstructured":"S\u00e1nchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, Wessale JL, Zhao L, Johnson RJ: Effect of febuxostat on the progression of renal disease in 5\/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol. 2008, 108: 69-78. 10.1159\/000127837.","journal-title":"Nephron Physiol"},{"key":"1916_CR41","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1081\/NCN-200027377","volume":"23","author":"S Hoshide","year":"2004","unstructured":"Hoshide S, Takahashi Y, Ishikawa T, Kubo J, Tsuchimoto M, Komoriya K, Ohno I, Hosoya T: PK\/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids. 2004, 23: 1117-1118. 10.1081\/NCN-200027377.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"1916_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/00045391-200501000-00005","volume":"12","author":"MD Mayer","year":"2005","unstructured":"Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ: Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther. 2005, 12: 22-34. 10.1097\/00045391-200501000-00005.","journal-title":"Am J Ther"},{"key":"1916_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","volume":"12","author":"CA Sarawate","year":"2006","unstructured":"Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW: Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol. 2006, 12: 61-65. 10.1097\/01.rhu.0000209882.50228.9f.","journal-title":"J Clin Rheumatol"},{"key":"1916_CR44","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","volume":"20","author":"N Dalbeth","year":"2007","unstructured":"Dalbeth N, Stamp L: Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial. 2007, 20: 391-395. 10.1111\/j.1525-139X.2007.00270.x.","journal-title":"Semin Dial"},{"key":"1916_CR45","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005, 353: 2450-2461. 10.1056\/NEJMoa050373.","journal-title":"N Engl J Med"},{"key":"1916_CR46","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher HR, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N: Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008, 59: 1540-1548. 10.1002\/art.24209.","journal-title":"Arthritis Rheum"},{"key":"1916_CR47","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/RHU.0b013e31821d36cc","volume":"17","author":"N Kamatani","year":"2011","unstructured":"Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y: An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol. 2011, 17: S13-S18. 10.1097\/RHU.0b013e31821d36cc.","journal-title":"J Clin Rheumatol"},{"key":"1916_CR48","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C: The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010, 12: R63-10.1186\/ar2978.","journal-title":"Arthritis Res Ther"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-15-26.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1745-6215-15-26\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-15-26.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T22:38:06Z","timestamp":1648075086000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/1745-6215-15-26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,16]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1916"],"URL":"https:\/\/doi.org\/10.1186\/1745-6215-15-26","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,16]]},"article-number":"26"}}